Immunovant, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Immunovant, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2018 to Q2 2024.
  • Immunovant, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$87.2M, a 17.9% decline year-over-year.
  • Immunovant, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$273M, a 11.5% decline year-over-year.
  • Immunovant, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$259M, a 22.9% decline from 2022.
  • Immunovant, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$211M, a 34.6% decline from 2021.
  • Immunovant, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$157M, a 45.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$273M -$87.2M -$13.2M -17.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$259M -$75.3M -$15.9M -26.7% Jan 1, 2024 Mar 31, 2024 10-K 2024-05-29
Q4 2023 -$243M -$51.4M +$11.8M +18.7% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-12
Q3 2023 -$255M -$58.7M -$10.7M -22.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-02-12
Q2 2023 -$245M -$73.9M -$33.6M -83.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$211M -$59.4M -$12.3M -26% Jan 1, 2023 Mar 31, 2023 10-K 2024-05-29
Q4 2022 -$199M -$63.2M -$21.8M -52.8% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 -$177M -$47.9M -$10.2M -27.1% Jul 1, 2022 Sep 30, 2022 10-Q 2024-02-12
Q2 2022 -$167M -$40.4M -$9.9M -32.5% Apr 1, 2022 Jun 30, 2022 10-Q 2024-02-12
Q1 2022 -$157M -$47.2M -$19M -67.5% Jan 1, 2022 Mar 31, 2022 10-K 2023-05-22
Q4 2021 -$138M -$41.4M -$9.61M -30.2% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-03
Q3 2021 -$128M -$37.7M -$16.9M -81.4% Jul 1, 2021 Sep 30, 2021 10-Q 2023-02-03
Q2 2021 -$111M -$30.5M -$3.76M -14.1% Apr 1, 2021 Jun 30, 2021 10-Q 2023-02-03
Q1 2021 -$107M -$28.2M -$7.61M -37% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-08
Q4 2020 -$99.8M -$31.8M -$20.5M -181% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-04
Q3 2020 -$79.3M -$20.8M -$6.31M -43.6% Jul 1, 2020 Sep 30, 2020 10-Q 2022-02-04
Q2 2020 -$73M -$26.7M -$6.65M -33.1% Apr 1, 2020 Jun 30, 2020 10-Q 2022-02-04
Q1 2020 -$66.4M -$20.6M -$20.6M Jan 1, 2020 Mar 31, 2020 10-K 2021-06-01
Q4 2019 -$45.8M -$11.3M -$2.45M -27.7% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 -$43.4M -$14.5M -$8.13M -128% Jul 1, 2019 Sep 30, 2019 10-Q 2021-02-16
Q2 2019 -$35.3M -$20.1M -$15.7M -359% Apr 1, 2019 Jun 30, 2019 10-Q 2021-02-16
Q1 2019 -$19.6M -$450* Jan 1, 2019 Mar 31, 2019 10-Q 2019-11-13
Q4 2018 -$8.85M Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 -$6.35M Jul 7, 2018 Sep 30, 2018 10-Q 2020-02-14
Q2 2018 -$4.37M Apr 1, 2018 Jun 30, 2018 10-Q 2020-02-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.